Misonix (MSON) 10-Q 7 May 15 2015 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Mar. 31, 2015	7-May-15
Document Information [Line Items]
Entity Registrant Name	MISONIX INC
Entity Central Index Key	880432
Current Fiscal Year End Date	-24
Entity Filer Category	Smaller Reporting Company
Trading Symbol	MSON
Entity Common Stock, Shares Outstanding		7,710,363
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2015

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Mar. 31, 2015	Jun. 30, 2014
Current assets:
Cash and cash equivalents	$8,909,275	$7,039,938
Accounts receivable, less allowance for doubtful accounts of $126,868 and $136,868, respectively	3,517,863	3,759,152
Inventories, net	4,164,341	4,217,350
Prepaid expenses and other current assets	529,698	367,830
Total current assets	17,121,177	15,384,270
Property, plant and equipment, net of accumulated amortization and depreciation of $5,399,621 and $4,842,009, respectively	1,893,873	1,517,852
Goodwill	1,701,094	1,701,094
Intangible and other assets	1,106,666	924,653
Total assets	21,822,810	19,527,869
Current liabilities:
Accounts payable	1,023,492	1,650,323
Accrued expenses and other current liabilities	1,357,223	1,457,250
Total current liabilities	2,380,715	3,107,573
Deferred lease liability	4,154	16,614
Deferred income	28,125	51,318
Total liabilities	2,412,994	3,175,505
Commitments and contingencies (Note 8)
Stockholders' equity:
Common stock, $.01 par value-shares authorized 20,000,000, 7,835,345 and 7,412,096 shares issued and 7,710,363 and 7,334,536 shares outstanding, respectively	78,353	74,121
Additional paid-in capital	30,019,375	28,169,622
Accumulated deficit	-9,741,652	-11,480,386
Treasury stock, at cost, 124,982 and 77,560 shares, respectively	-946,260	-410,993
Total stockholders' equity	19,409,816	16,352,364
Total liabilities and stockholders' equity	$21,822,810	$19,527,869

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Jun. 30, 2014
Allowance for doubtful accounts (in dollars)	$126,868	$136,868
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment (in dollars)	$5,399,621	$4,842,009
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, shares authorized	20,000,000	20,000,000
Common stock, shares issued	7,835,345	7,412,096
Common stock, shares outstanding	7,710,363	7,334,536
Treasury stock, shares	124,982	77,560

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	3 Months Ended		9 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Net sales	$5,314,797	$4,284,645	$15,455,142	$11,482,288
Cost of goods sold	1,670,359	1,431,766	5,023,639	4,006,505
Gross profit	3,644,438	2,852,879	10,431,503	7,475,783
Operating expenses:
Selling expenses	2,465,803	1,913,795	6,570,263	5,426,324
General and administrative expenses	1,583,399	1,176,047	4,364,261	3,518,288
Research and development expenses	407,773	406,466	1,169,665	1,314,373
Total operating expenses	4,456,975	3,496,308	12,104,189	10,258,985
Loss from operations	-812,537	-643,429	-1,672,686	-2,783,202
Other income (expense):
Interest income	12	18	56	56
Royalty income and license fees	1,032,027	830,702	3,224,919	2,552,888
Other	-6,452	-5,121	-16,978	-16,686
Total other income	1,025,587	825,599	3,207,997	2,536,258
Income/(loss) from continuing operations before income taxes	213,050	182,170	1,535,311	-246,944
Income tax expense	8,406	8,376	56,223	13,876
Net income/(loss) from continuing operations	204,644	173,794	1,479,088	-260,820
Discontinued operations:
Income from discontinued operations net of tax expense of $0 and $0, respectively	4,976	4,976	14,926	14,926
Gain from sale of discontinued operations net of tax expense of $5,280 and $0, respectively	244,720	250,000	244,720	250,000
Net income from discontinued operations	249,696	254,976	259,646	264,926
Net income	$454,340	$428,770	$1,738,734	$4,106
Net income/(loss) per share from continuing operations - Basic (in dollars per share)	$0.03	$0.02	$0.20	($0.04)
Net income per share from discontinued operations - Basic (in dollars per share)	$0.03	$0.04	$0.03	$0.04
Net income per share - Basic (in dollars per share)	$0.06	$0.06	$0.23	$0
Net income/(loss) per share from continuing operations - Diluted (in dollars per share)	$0.02	$0.02	$0.18	($0.04)
Net income per share from discontinued operations - Diluted (in dollars per share)	$0.03	$0.03	$0.03	$0.04
Net income per share - Diluted (in dollars per share)	$0.05	$0.05	$0.21	$0
Weighted average shares - Basic (in shares)	7,675,520	7,249,725	7,533,608	7,209,037
Weighted average shares - Diluted (in shares)	8,313,674	7,930,802	8,042,976	7,209,037

Consolidated_Statements_of_Ope1

Consolidated Statements of Operations (Parenthetical) (USD $)	3 Months Ended		9 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Income from discontinued operations, Tax expense	$0	$0	$0	$0
Discontinued Operation, Tax Effect Of Discontinued Operation	$5,280	$0	$5,280	$0

Consolidated_Statement_of_Stoc

Consolidated Statement of Stockholders' Equity (USD $)	Total	Common Stock [Member]	Treasury Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]
Balance at Jun. 30, 2014	$16,352,364	$74,121	($410,993)	$28,169,622	($11,480,386)
Balance (in shares) at Jun. 30, 2014		7,412,096	-77,560
Net income/comprehensive income	1,738,734	0	0	0	1,738,734
Proceeds from exercise of stock options	555,897	4,232	-535,267	1,086,932	0
Proceeds from exercise of stock options (in shares)		423,249	-47,422
Stock-based compensation	762,821	0	0	762,821	0
Balance at Mar. 31, 2015	$19,409,816	$78,353	($946,260)	$30,019,375	($9,741,652)
Balance (in shares) at Mar. 31, 2015		7,835,345	-124,982

Consolidated_Statement_of_Stoc1

Consolidated Statement of Stockholders' Equity (Parenthetical) (USD $)	Mar. 31, 2015	Jun. 30, 2014
Common Stock, Par Value (in dollars per share)	$0.01	$0.01

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	9 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Operating activities
Net income/(loss) from continuing operations	$1,479,088	($260,820)
Adjustments to reconcile net income/(loss) to net cash provided by/(used in) by continuing operating activities:
Depreciation and amortization and other non-cash items	1,003,076	712,418
Bad debt expense	-10,000	-42,773
Stock-based compensation	762,821	509,396
Deferred income	-32,830	-2,745
Deferred lease liability	-12,460	-5,398
Changes in operating assets and liabilities:
Accounts receivable	251,289	62,134
Inventories	-797,027	-733,723
Prepaid expenses and other assets	-232,794	95,050
Accounts payable, accrued expenses and other non-cash items	-717,221	-973,613
Net cash provided by/(used in) continuing operating activities	1,693,942	-640,074
Investing activities
Acquisition of property, plant and equipment	-222,052	-61,257
Payments for asset acquisition	-328,136	0
Additional patents	-89,960	-85,087
Net cash used in investing activities	-640,148	-146,344
Financing activities
Proceeds from exercise of stock options	555,897	363,255
Net cash provided by financing activities	555,897	363,255
Cash flows from discontinued operations
Net cash provided by operating activities	14,926	14,926
Net cash provided by investing activities	244,720	250,000
Net cash provided by discontinued operations	259,646	264,926
Net increase/(decrease) in cash and cash equivalents	1,869,337	-158,237
Cash and cash equivalents at beginning of period	7,039,938	5,806,437
Cash and cash equivalents at end of period	8,909,275	5,648,200
Supplemental disclosure of cash flow information:
Income taxes	$73,568	$17,076

Basis_of_Presentation

Basis of Presentation	9 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies [Text Block]	1. Basis of Presentation
	The accompanying unaudited financial information should be read in conjunction with the audited consolidated financial statements and the notes thereto included in the Annual Report on Form 10-K for the year ended June 30, 2014 (“2014 Annual Report”) of MISONIX, INC. (“Misonix” or the “Company”). A summary of the Company’s significant accounting policies is identified in Note 1 of the notes to the consolidated financial statements included in the Company’s 2014 Annual Report. There have been no changes in the Company’s significant accounting policies subsequent to June 30, 2014.
	The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X pursuant to the requirements of the U.S. Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. The results of operations for the interim periods are not necessarily indicative of the results of operations for the entire year.
	The consolidated financial statements of the Company include the accounts of Misonix and its 100% owned subsidiaries, Fibra-Sonics (NY) Inc. and Hearing Innovations, Inc. All significant intercompany balances and transactions have been eliminated.
	Organization and Business
	Misonix is a surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide for spine surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications.
	The Company’s revenues are generated from various regions throughout the world. Sales by the Company outside the United States are made primarily through distributors. Sales made in the United States are made primarily through representative agents. The following is an analysis of net sales from continuing operations by geographic region:
		Three months ended March 31,
		2015		2014
	United States	$	2,607,023	$	2,258,370
	Australia		161,858		40,805
	Europe		866,726		834,195
	Asia		1,016,518		688,432
	Canada and Mexico		272,700		183,827
	South America		96,087		100,373
	South Africa		64,535		156,403
	Middle East		229,350		22,240
		$	5,314,797	$	4,284,645
		Nine months ended March 31,
		2015		2014
	United States	$	7,709,102	$	5,667,183
	Australia		313,221		116,158
	Europe		2,590,616		1,587,486
	Asia		2,759,121		2,025,492
	Canada and Mexico		513,916		616,172
	South America		615,295		810,977
	South Africa		245,151		322,097
	Middle East		708,720		336,723
		$	15,455,142	$	11,482,288
	On February 1, 2015, the Company entered into an agreement with Aesculap, Inc. (“Aesculap”) to buy back certain accounts that were protected under the termination agreement entered into by Misonix and Aesculap on December 31, 2012 (the “Termination Agreement”). The Termination Agreement allowed Aesculap to continue to sell and service key accounts which were defined as accounts maintaining a specified revenue level on average over a three year term which was due to expire on December 31, 2015. The buy back amount total is $328,136 and one half was paid on February 1, 2015 and the balance was paid on March 1, 2015. The total buy back amount includes $28,867 worth of units that will be for customer use and is expected to be fully utilized. The buy back has been recorded as reacquired contractual rights in intangible and other assets and will be amortized over the period through December 31, 2015.
	Discontinued Operations
	Laboratory and Forensic Safety Products Business
	On October 19, 2011, Misonix sold its Laboratory Products business, which comprised substantially all of the Laboratory and Scientific Products segment, to Mystaire, Inc. (“Mystaire”) for $1.5 million in cash plus a potential additional payment of up to an aggregate $500,000 based upon 30% of net sales in excess of $2.0 million for each of the three years following the closing (the “earn-out”). The Laboratory and Forensic Safety Products business manufactured and marketed ductless fume, laminar airflow and polymerase chain reaction workstations both domestically and internationally. The earn-out will not be factored into the gain on sale until it is earned by Misonix. The earn-out period ended October 19, 2014 with no earn-out having been recorded.
	High Intensity Focused Ultrasound Technology
	In consideration for the May 2010 sale of its rights to the high intensity focused ultrasound technology to USHIFU LLC, now SonaCare, Misonix will receive up to approximately $5.8 million, paid out of an earn-out of 7% of gross revenues received from Sonicare’s sales of the (i) prostate product in Europe and (ii) kidney and liver products around the world related to the business being sold up to the time the Company has received the first $3 million and thereafter 5% of the gross revenues up to $5.8 million. Commencing 90 days after each December 31st and beginning December 31, 2011 the payments will be the greater of (a) $250,000 or (b) 7% of gross revenues received up to the time the Company has received the first $3 million and thereafter 5% of gross revenues up to the $5.8 million. Cumulative payments through March 31, 2015 were $1,004,788.
	Results of Discontinued Operations
		For the three months ended				For the nine months ended
		March 31,				March 31,
		2015		2014		2015		2014
	Revenues	$	4,976	$	4,976	$	14,926	$	14,926
	Income from discontinued operations, before tax	$	4,976	$	4,976	$	14,926	$	14,926
	Gain on sale of discontinued operations		250,000		250,000		250,000		250,000
	Income tax expense		-5,280		-		-5,280		-
	Net income from discontinued operations, net of tax	$	249,696	$	254,976	$	259,646	$	264,926
	Accounts Receivable
	Accounts receivable, principally trade, are generally due within 30 to 90 days and are stated at amounts due from customers, net of an allowance for doubtful accounts. The Company performs ongoing credit evaluations and adjusts credit limits based upon payment history and the customer’s current credit worthiness, as determined by a review of their current credit information. The Company continuously monitors aging reports, collections and payments from customers and maintains a provision for estimated credit losses based upon historical experience and any specific customer collection issues that have been identified. While such credit losses have historically been within expectations and the provisions established, the Company cannot guarantee that the same credit loss rates will be experienced in the future. The Company writes off accounts receivable when they become uncollectible.

Income_Loss_Per_Share_of_Commo

Income (Loss) Per Share of Common Stock	9 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	2. Income (Loss) Per Share of Common Stock
	Basic income (loss) per common share (“basic EPS”) is computed by dividing income (loss) by the weighted average number of common shares outstanding for the period. Diluted income (loss) per common share (“diluted EPS”) is computed by dividing income (loss) by the weighted average number of common shares and dilutive common share equivalents outstanding (consisting of outstanding common stock options) for the period.
	The number of weighted average common shares used in the calculation of basic EPS and diluted EPS were as follows:
		For the nine months ended				For the three months ended
		March 31,				March 31,
		2015		2014		2015		2014
	Basic shares		7,533,608		7,209,037		7,675,520		7,249,725
	Dilutive effect of stock options		509,368		-		638,154		681,077
	Diluted shares		8,042,976		7,209,037		8,313,674		7,930,802
	Excluded from the calculations of diluted EPS are options to purchase 92,000 shares of common stock for the three and nine months ended March 31, 2015 and 166,800 shares of common stock for the three months ended March 31, 2014, as the exercise prices exceeded the average market prices during these periods.
	Diluted EPS for the nine months ended March 31, 2014 presented is the same as basic EPS as the inclusion of the effect of common share equivalents then outstanding would be anti-dilutive. For this reason, excluded from the calculation of diluted EPS are outstanding options to purchase 1,732,829 shares of common stock for the nine months ended March 31, 2014.

Comprehensive_IncomeLoss

Comprehensive Income/(Loss)	9 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Comprehensive Income (Loss) Note [Text Block]	3. Comprehensive Income/(Loss)
	Total comprehensive income was $1,738,734 and $4,106 for the nine months ended March 31, 2015 and 2014, respectively. Total comprehensive income was $454,340 and $428,770 for the three months ended March 31, 2015 and 2014, respectively. There are no components of comprehensive income other than net income for all periods presented.

StockBased_Compensation

Stock-Based Compensation	9 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	4. Stock-Based Compensation
	Stock options are granted with exercise prices not less than the fair market value of our common stock at the time of the grant, with an exercise term (as determined by the committee administering the applicable option plan (the “Committee”)) not to exceed 10 years. The Committee determines the vesting period for the Company’s stock options. Generally, such stock options have vesting periods of immediate to four years. Certain option awards provide for accelerated vesting upon meeting specific retirement, death or disability criteria and upon a change in control. During the nine month periods ended March 31, 2015 and 2014, the Company granted options to purchase 369,000 and 324,000 shares of the Company’s common stock, respectively.
	Stock-based compensation expense for the nine month periods ended March 31, 2015 and 2014 was approximately $763,000 and $509,000, respectively. Compensation expense is recognized in the general and administrative expenses line item of the Company’s consolidated statements of operations on a straight-line basis over the vesting periods. As of March 31, 2015, there was approximately $2,920,000 of total unrecognized compensation cost related to non-vested stock-based compensation arrangements to be recognized over a weighted-average period of 3.0 years.
	Shares may be acquired by various methods. They may be acquired by (a) cash or by certified check, (b) with previously acquired shares of common stock having an aggregate fair market value, on the date of exercise, equal to the aggregate exercise price of all options being exercised (provided that such shares were not acquired less than six (6) months prior to such exercise date), (c) by surrendering options to acquire shares of common stock in exchange for the number of shares of common stock equal to the product of the number of shares of common stock as to which the option is being exercised multiplied by a fraction, the numerator of which is the fair market value of the common stock less the exercise price of the options and the denominator of which is such fair market value. Cash in the amount of $555,897 was received from the exercise of stock options for the nine months ended March 31, 2015. The Company received 47,422 shares of previously acquired common stock as payment for option exercises for the nine months ended March 31, 2015. The acquired shares are held and accounted for as treasury stock. Total options, exercised by either cash or through surrender of previously owned shares, were 545,713. The total number of options forfeited for the nine months ended March 31, 2015 was 13,500 options, representing the unvested portion upon termination of employment. Options expiring at the end of the option term totaled 28,000 for the nine months ended March 31, 2015.
	The fair values of the options granted during the nine months ended March 31, 2015 and 2014 were primarily estimated on the date of the grant using the Black-Scholes option-pricing model on the basis of the following weighted average assumptions during the respective periods:
			For the nine months ended
			March 31,
			2015			2014
	Risk-free interest rate			0.97	%		3	%
	Expected option life in years			6.5			6.5
	Expected stock price volatility			73.46	%		76.1	%
	Expected dividend yield			0	%		0	%
	Weighted-average fair value of options granted		$	5.46		$	3.95
	The expected option term is based upon the number of years the Company estimates the option will be outstanding based on historical exercises and terminations. The expected volatility for the expected life of the options is determined using historical price changes of the Company’s stock over a period equal to that of the expected life of the options. The risk free rate is based upon the U.S. Treasury yield in effect at the time of the grant. The expected dividend yield is 0% as the Company has historically not declared dividends and does not anticipate declaring any in the future.
	Changes in outstanding stock options during the nine months ended March 31, 2015 were as follows:
			Options
									Weighted
									Average
						Weighted			Remaining
						Average			Contractual		Aggregate
			Number of			Exercise			Life		Intrinsic
			Shares			Price ($)			(years)		Value (a)
	Outstanding as of June 30, 2014			1,663,329			3.88
	Granted			369,000			9.05
	Exercised			-545,713			4.06				$	1,478,776
	Forfeited			-13,500			4.01
	Expired			-28,000			8
	Outstanding as of March 31, 2015			1,445,116			5.05			6.6	$	11,576,608
	Exercisable and vested at March 31, 2015			650,256			3.27			5.3	$	6,362,511
	Available for grant as of March 31, 2015			958,975	*
	(a)	Intrinsic value for purposes of this table represents the amount by which the fair value of the underlying stock, based on the respective market prices at March 31, 2015 or if exercised, the exercise dates, exceeds the exercise prices of the respective options.
	*	Includes the recent 750,000 share 2014 Employee Equity Incentive Plan approved by shareholders at the annual meeting held on February 3, 2015.

Income_Taxes

Income Taxes	9 Months Ended
	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	5. Income Taxes
	For the nine months ended March 31, 2015, the Company recorded an income tax expense from continuing operations of $56,223.
	For the nine months ended March 31, 2015 and 2014, the effective rate of 4% and (6%), respectively, on continuing operations varied from the U.S. federal statutory rate primarily due to permanent book tax differences, state taxes and a change in the valuation allowance.
	The Company established a valuation against the deferred tax asset in prior years when management concluded that it is more likely than not that the deferred tax asset may not be fully realized. Management’s deferred tax asset assessment on realizability is unchanged as of March 31, 2015. The Company’s estimated annual effected tax rate reflects a reduction in the valuation allowance related to income in the current year.
	As of March 31, 2015 and June 30, 2014, the Company has no material unrecognized tax benefits or accrued interest and penalties.

Inventories

Inventories	9 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	6. Inventories
	Inventories are summarized as follows:
		March 31,		June 30,
		2015		2014
	Raw material	$	2,056,238	$	1,820,046
	Work-in-process		521,669		410,827
	Finished goods		2,602,328		3,337,568
			5,180,235		5,568,441
	Less valuation reserve		1,015,894		1,351,091
		$	4,164,341	$	4,217,350

Accrued_Expenses_and_Other_Cur

Accrued Expenses and Other Current Liabilities	9 Months Ended
	Mar. 31, 2015
Payables and Accruals [Abstract]
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	7. Accrued Expenses and Other Current Liabilities
	The following summarizes accrued expenses and other current liabilities:
		March 31,		June 30,
		2015		2014
	Accrued payroll and vacation	$	463,188	$	460,341
	Accrued bonuses		225,000		250,000
	Accrued commissions		331,000		340,462
	Accrued professional and legal fees		86,378		85,832
	Deferred income		46,403		102,453
	Other		205,254		218,162
		$	1,357,223	$	1,457,250

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	8. Commitments and Contingencies
	Employment Agreement
	On July 1, 2014 the Company entered into a new Employment Agreement with Michael A. McManus, Jr., whereby he will continue to serve as the Company’s President and Chief Executive Officer (the “Agreement”). The Agreement has an initial term expiring June 30, 2015 and renews for successive one-year periods thereafter unless terminated by either party not less than ninety (90) days prior to the end of the then-current term. The Agreement provides for an annual base salary of $299,000, and an annual bonus based on Mr. McManus’ achievement of annual goals and objectives as determined by the Compensation Committee of the Company’s Board of Directors.
	Mr. McManus is entitled under the Agreement to participate in any plans and programs made available to the executive employees of the Company generally.
	The Company can terminate the Agreement for cause (as defined in the Agreement). Mr. McManus can terminate the Agreement for Good Reason (as defined in the Agreement). If Mr. McManus terminates the Agreement for Good Reason, the Company must pay him an amount equal to two times his total compensation (annual base salary plus bonus) at the highest rate paid him at any time during the aggregate time he has been employed by the Company, payable in a lump sum within sixty (60) days of termination of employment.
	Mr. McManus is entitled to severance pay and benefits if he terminates his employment with the Company following a Change in Control (as defined in the Agreement), to provide him with an incentive to remain with the Company and consummate a strategic corporate sale or transaction that maximizes shareholder value. Severance pay and benefits are triggered upon (i) his Involuntary Termination without Cause (as defined in the Agreement) for a reason other than death or Disability (as defined in the Agreement) or (ii) as a result of a Constructive Termination (as defined in the Agreement) which in either case occurs: (x) during the period not to exceed twenty-four (24) months after the effective date of a Change in Control, or (y) before the effective date of a Change in Control, but after the first date on which the Board of Directors and/or senior management of the Company has entered into formal negotiations with a potential acquirer that results in the consummation of a Change in Control.
	In the event that pay and benefits are triggered, Mr. McManus (A) is entitled to receive severance pay in an amount equal to two (2) times the sum of (a) his annual base pay and (b) bonus at the highest rate paid him for any fiscal year during the aggregate period of his employment by the Company, payable in cash in a lump sum; the payment of premiums for medical, dental, vision, hospitalization and long term care coverage under Company plans for a period of twenty-four (24) months; (B) has the right, for a period of (i) ninety (90) days for stock options granted under any of the Company’s Employee Stock Option Plans adopted prior to 2005 and (ii) two (2) years for stock options granted under the Company’s 2005 Employee Equity Incentive Plan, 2009 Employee Equity Incentive Plan, 2012 Employee Equity Incentive Plan and any Plan adopted after the effective date of the Agreement following his Termination Date (as defined in the Agreement), to exercise the options to the extent such options are otherwise vested and exercisable as of the Termination Date under the terms of the applicable stock option agreement(s) and Plan(s); and (C) will vest in all unvested stock option grants with respect to options granted after July 1, 2012.
	Mr. McManus has also agreed in the Agreement to an eighteen (18) month post-termination covenant not-to-compete, as well as other customary covenants concerning non-solicitation and non-disclosure of confidential information of the Company.
	The Company and Mr. McManus had previously entered into two letter agreements (the “Letter Agreements”) providing for the exercise of vested options by Mr. McManus (i) for a ninety (90) day period after his retirement with respect to stock options granted under certain of the Company’s stock option plans and (ii) for two (2) years after Mr. McManus terminates his employment with the Company in the event of a Change-in-Control (as defined in the applicable stock option plans) and he is eligible for the severance benefits provided for by the Agreement. The Company and Mr. McManus have entered into a letter agreement which makes clear that the terms and conditions of the Letter Agreements continue to be in full force and effect and apply to the Agreement.
	Contingencies
	The Company and its subsidiaries are from time to time involved in ordinary and routine litigation. Management presently believes that the ultimate outcome of these proceedings, individually or in the aggregate, will not have a material adverse effect on the Company’s financial position, cash flows or result of operations.
	Nevertheless, litigation is subject to inherent uncertainties and an unfavorable ruling could occur.  An unfavorable ruling could include money damages and in such event, could result in a material adverse impact on the Company’s results of operations in the year in which the ruling occurs.
	On July 19, 2011, Misonix entered into a Distribution Agreement (the “Distribution Agreement”) with PuriCore, Inc. (“PuriCore”). Pursuant to the Distribution Agreement, the Company had been granted the right to distribute PuriCore’s Vashe® solution products in the United States, on a private label basis and known as the Misonix Soma product, as an antibacterial, antimicrobial irrigating solution for the treatment of human wound care in conjunction with therapeutic ultrasonic procedures (the “Field”). PuriCore had agreed, subject to modification, not to sell the products that were the subject of the Distribution Agreement (the “Licensed Products”) to any other therapeutic ultrasound company for distribution in the Field in the United States (“Exclusivity”). The Company had agreed not to sell or distribute in the United States in the Field any irrigating solution that has anti-microbial properties other than the Licensed Products so long as the Company had Exclusivity.
	During our fiscal fourth quarter 2013, the Company sent a notice to terminate the Distribution Agreement due to management’s belief that the products subject to the Distribution Agreement were non-conforming. PuriCore disputed the Company’s ability to terminate the Distribution Agreement. On October 11, 2013, the Company and PuriCore mutually terminated the Distribution Agreement and signed a Settlement Agreement resolving all issues without the payment of any monies by either party. A reversal of the previously accrued and unpaid contractual minimum gross profit requirement in the amount of $439,508 was made through cost of goods sold in the quarter ended December 31, 2013 as a result of the Settlement Agreement. There are no further commitments to PuriCore.

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments	9 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	9. Fair Value of Financial Instruments
	We follow a three-level fair value hierarchy that prioritizes the inputs to measure fair value. This hierarchy requires entities to maximize the use of “observable inputs” and minimize the use of “unobservable inputs.” The three levels of inputs used to measure fair value are as follows:
	Level 1: Quoted prices (unadjusted) for identical assets or liabilities in active markets as of the measurement date.
	Level 2: Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.
	Level 3: Significant unobservable inputs that reflect assumptions that market participants would use in pricing an asset or liability.
	The following is a summary of the carrying amounts and estimated fair values of our financial instruments at March 31, 2015 and June 30, 2014:
	March 31, 2015	Carrying Amount		Fair Value
	Cash and cash equivalents	$	8,909,275	$	8,909,275
	Trade accounts receivable		3,517,863		3,517,863
	Trade accounts payable		1,023,492		1,023,492
	June 30, 2014	Carrying Amount		Fair Value
	Cash and cash equivalents	$	7,039,938	$	7,039,938
	Trade accounts receivable		3,759,152		3,759,152
	Trade accounts payable		1,650,323		1,650,323
	The following methods and assumptions were used to estimate the fair value of each class of financial instruments for which it is practicable to estimate that value:
	Cash and cash equivalents
	The carrying amount approximates fair value because of the short maturity of those instruments.
	Trade Accounts Receivable
	The carrying amount of trade receivables reflects net recovery value and approximates fair value because of their short outstanding terms.
	Trade Accounts Payable
	The carrying amount of trade payables approximates fair value because of their short outstanding terms.
	Non-financial assets and liabilities
	Certain non-financial assets and liabilities, principally goodwill, are measured at fair value on a non-recurring basis; that is the assets and liabilities are not measured at fair value on an ongoing basis but are subject to fair value adjustments in certain circumstances, such as when evidence of impairment exists. At March 31, 2015, no fair value adjustments or material fair value measurements were required for non-financial assets or liabilities.

Goodwill_and_Intangible_Assets

Goodwill and Intangible Assets	9 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets Disclosure [Text Block]	10. Goodwill and Intangible Assets
	Goodwill is not amortized. We review goodwill for impairment annually and whenever events or changes indicate that the carrying value of an asset may not be recoverable. These events or circumstances could include a significant change in the business climate, legal factors, operating performance indicators, competition, or sale or disposition of significant assets or product lines. Application of these impairment tests requires significant judgments, including estimation of cash flows, which is dependent on internal forecasts, estimation of the long-term rate of growth for our business, estimation of the useful life over which cash flows will occur and determination of our weighted-average cost of capital. We primarily use a discounted cash flow model in determining fair value, which consists of level three inputs. Changes in the projected cash flows and discount rate estimates and assumptions underlying the valuation of goodwill could materially affect the determination of fair value at acquisition or during subsequent periods when tested for impairment. The Company determined that there were no indicators that the recorded goodwill was impaired as of March 31, 2015 which required further testing.
	The cost of acquiring or processing patents is capitalized. This amount is being amortized using the straight-line method over the estimated useful lives of the underlying assets, which is approximately 17 years. Net patents reported in intangible and other assets totaled $573,967 and $611,355 at March 31, 2015 and June 30, 2014, respectively. Accumulated amortization totaled $768,817 and $641,469 at March 31, 2015 and June 30, 2014, respectively. Amortization expense for the three month periods ended March 31, 2015 and 2014 was approximately $22,000 and $22,000, respectively. Amortization expense for the nine month periods ended March 31, 2015 and 2014 was $127,000 and $63,000, respectively.
	Net customer relationships reported in intangible and other assets totaled $80,000 and $200,000 at March 31, 2015 and June 30, 2014, respectively. Accumulated amortization amounted to $720,000 at March 31, 2015 and $600,000 at June 30, 2014. Amortization expense for the three months ended March 31, 2015 and 2014 was $40,000. Amortization expense for the nine month period ended March 31, 2015 and 2014 was $120,000.
	Net reacquired contractual rights from Aesculap reported in intangible and other assets totaled $268,475 at March 31, 2015 and $0 at June 30, 2014. Accumulated amortization amounted to $59,661 at March 31, 2015 and $0 at June 30, 2014. Amortization expense for the nine months ended March 31, 2015 and 2014 was $59,661 and $0, respectively.
	The following is a schedule of estimated future amortization expense as of March 31, 2015:
				Customer		Reacquired
		Patents		Relationships		Contractual Rights
	2015	$	22,446	$	40,000	$	89,492
	2016		83,519		40,000		178,983
	2017		78,424		-		-
	2018		75,843		-		-
	2019		68,314		-		-
	Thereafter		245,421		-		-
		$	573,967	$	80,000	$	268,475

Recent_Accounting_Pronouncemen

Recent Accounting Pronouncements	9 Months Ended
	Mar. 31, 2015
Accounting Changes and Error Corrections [Abstract]
Description of New Accounting Pronouncements Not yet Adopted [Text Block]	11. Recent Accounting Pronouncements
	In April 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-08, “Presentation of Financial Statements (Topic 205)” and “Property, Plant and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity.” The amendments in the ASU change the criteria for reporting discontinued operations while enhancing related disclosures. The amendments in the ASU are effective in the first quarter of 2015. The adoption of ASU 2014-08 did not have a material impact on the Company’s consolidated financial statements.
	In May 2014, the FASB issued ASU 2014-09, "Revenue from Contracts with Customers (Topic 606)." The new revenue recognition standard provides a five-step analysis to determine when and how revenue is recognized.  The standard requires that a company recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. This ASU is effective for annual periods beginning after December 15, 2016 and will be applied retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption.  The Company is currently evaluating the impact of the pending adoption of ASU 2014-09 on its consolidated financial statements.

Related_Party_Transactions

Related Party Transactions	9 Months Ended
	Mar. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	12. Related Party Transactions
	Stavros G. Vizirgianakis was appointed to Misonix’s Board of Directors on May 7, 2013. During the fiscal year ended June 30, 2014, Mr. Vizirgianakis owned (i) a controlling interest in MD Solutions Australasia PTY Ltd. (“MD Solutions”) and (ii) an interest in Surgical Innovations (“SI”). MD Solutions is an independent distributor for the Company outside of the United States. Applied BioSurgical, a company owned by Mr. Vizirgianakis’ father, is an independent distributor for the Company outside of the United States. SI purchased certain of the Company’s products from Applied BioSurgical during the fiscal year ended June 30, 2014. Mr. Vizirgianakis disposed of his interest in each of MD Solutions and SI during the fiscal year ended June 30, 2014.
	Set forth below is a table showing the Company’s net sales and accounts receivable for the indicated time periods below with Applied BioSurgical and MD Solutions:
	For the nine months ended March 31,
	Applied BioSurgical	2015		2014
	Sales	$	245,151	$	322,097
	Accounts receivable		64,534		130,354
	MD Solutions	2014
	Australasia PTY Ltd.
	Sales	$	116,158
	Accounts receivable		13,713
	For the three months ended March 31,
	Applied BioSurgical	2015		2014
	Sales	$	64,534	$	156,403
	Accounts receivable		64,534		130,354
	MD Solutions	2014
	Australasia PTY Ltd.
	Sales	$	40,805
	Accounts receivable		13,713

Licensing_Agreements_for_Medic

Licensing Agreements for Medical Technology	9 Months Ended
	Mar. 31, 2015
Licensing Agreements For Medical Technology [Abstract]
Licensing Agreements For Medical Technology [Text Block]	13.  Licensing Agreements for Medical Technology
	In October 1996, the Company entered into a License Agreement (the "USS License") with United States Surgical (now, Covidien plc) for a twenty-year period, expiring October 2016, covering the further development and commercial exploitation of the Company's medical technology relating to laparoscopic products, which uses high frequency sound waves to coagulate and divide tissue for both open and laparoscopic surgery.
	The USS License gives Covidien exclusive worldwide marketing and sales rights for this technology. Under the USS License, the Company has received $475,000 in licensing fees (which are being recorded as income over the term of the USS License or 20 years), plus royalties based upon net sales of AutoSonix products. Total royalties from sales of this device were approximately $3,140,000 and $2,463,000 for the nine months ended March 31, 2015 and 2014, respectively.

Basis_of_Presentation_Policies

Basis of Presentation (Policies)	9 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]	Organization and Business
	Misonix is a surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide for spine surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications.
	The Company’s revenues are generated from various regions throughout the world. Sales by the Company outside the United States are made primarily through distributors. Sales made in the United States are made primarily through representative agents. The following is an analysis of net sales from continuing operations by geographic region:
		Three months ended March 31,
		2015		2014
	United States	$	2,607,023	$	2,258,370
	Australia		161,858		40,805
	Europe		866,726		834,195
	Asia		1,016,518		688,432
	Canada and Mexico		272,700		183,827
	South America		96,087		100,373
	South Africa		64,535		156,403
	Middle East		229,350		22,240
		$	5,314,797	$	4,284,645
		Nine months ended March 31,
		2015		2014
	United States	$	7,709,102	$	5,667,183
	Australia		313,221		116,158
	Europe		2,590,616		1,587,486
	Asia		2,759,121		2,025,492
	Canada and Mexico		513,916		616,172
	South America		615,295		810,977
	South Africa		245,151		322,097
	Middle East		708,720		336,723
		$	15,455,142	$	11,482,288
	On February 1, 2015, the Company entered into an agreement with Aesculap, Inc. (“Aesculap”) to buy back certain accounts that were protected under the termination agreement entered into by Misonix and Aesculap on December 31, 2012 (the “Termination Agreement”). The Termination Agreement allowed Aesculap to continue to sell and service key accounts which were defined as accounts maintaining a specified revenue level on average over a three year term which was due to expire on December 31, 2015. The buy back amount total is $328,136 and one half was paid on February 1, 2015 and the balance was paid on March 1, 2015. The total buy back amount includes $28,867 worth of units that will be for customer use and is expected to be fully utilized. The buy back has been recorded as reacquired contractual rights in intangible and other assets and will be amortized over the period through December 31, 2015.
Discontinued Operations, Policy [Policy Text Block]	Discontinued Operations
	Laboratory and Forensic Safety Products Business
	On October 19, 2011, Misonix sold its Laboratory Products business, which comprised substantially all of the Laboratory and Scientific Products segment, to Mystaire, Inc. (“Mystaire”) for $1.5 million in cash plus a potential additional payment of up to an aggregate $500,000 based upon 30% of net sales in excess of $2.0 million for each of the three years following the closing (the “earn-out”). The Laboratory and Forensic Safety Products business manufactured and marketed ductless fume, laminar airflow and polymerase chain reaction workstations both domestically and internationally. The earn-out will not be factored into the gain on sale until it is earned by Misonix. The earn-out period ended October 19, 2014 with no earn-out having been recorded.
	High Intensity Focused Ultrasound Technology
	In consideration for the May 2010 sale of its rights to the high intensity focused ultrasound technology to USHIFU LLC, now SonaCare, Misonix will receive up to approximately $5.8 million, paid out of an earn-out of 7% of gross revenues received from Sonicare’s sales of the (i) prostate product in Europe and (ii) kidney and liver products around the world related to the business being sold up to the time the Company has received the first $3 million and thereafter 5% of the gross revenues up to $5.8 million. Commencing 90 days after each December 31st and beginning December 31, 2011 the payments will be the greater of (a) $250,000 or (b) 7% of gross revenues received up to the time the Company has received the first $3 million and thereafter 5% of gross revenues up to the $5.8 million. Cumulative payments through March 31, 2015 were $1,004,788.
	Results of Discontinued Operations
		For the three months ended				For the nine months ended
		March 31,				March 31,
		2015		2014		2015		2014
	Revenues	$	4,976	$	4,976	$	14,926	$	14,926
	Income from discontinued operations, before tax	$	4,976	$	4,976	$	14,926	$	14,926
	Gain on sale of discontinued operations		250,000		250,000		250,000		250,000
	Income tax expense		-5,280		-		-5,280		-
	Net income from discontinued operations, net of tax	$	249,696	$	254,976	$	259,646	$	264,926
Receivables, Policy [Policy Text Block]	Accounts Receivable
	Accounts receivable, principally trade, are generally due within 30 to 90 days and are stated at amounts due from customers, net of an allowance for doubtful accounts. The Company performs ongoing credit evaluations and adjusts credit limits based upon payment history and the customer’s current credit worthiness, as determined by a review of their current credit information. The Company continuously monitors aging reports, collections and payments from customers and maintains a provision for estimated credit losses based upon historical experience and any specific customer collection issues that have been identified. While such credit losses have historically been within expectations and the provisions established, the Company cannot guarantee that the same credit loss rates will be experienced in the future. The Company writes off accounts receivable when they become uncollectible.

Basis_of_Presentation_Tables

Basis of Presentation (Tables)	9 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]	The following is an analysis of net sales from continuing operations by geographic region:
		Three months ended March 31,
		2015		2014
	United States	$	2,607,023	$	2,258,370
	Australia		161,858		40,805
	Europe		866,726		834,195
	Asia		1,016,518		688,432
	Canada and Mexico		272,700		183,827
	South America		96,087		100,373
	South Africa		64,535		156,403
	Middle East		229,350		22,240
		$	5,314,797	$	4,284,645
		Nine months ended March 31,
		2015		2014
	United States	$	7,709,102	$	5,667,183
	Australia		313,221		116,158
	Europe		2,590,616		1,587,486
	Asia		2,759,121		2,025,492
	Canada and Mexico		513,916		616,172
	South America		615,295		810,977
	South Africa		245,151		322,097
	Middle East		708,720		336,723
		$	15,455,142	$	11,482,288
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]		For the three months ended				For the nine months ended
		March 31,				March 31,
		2015		2014		2015		2014
	Revenues	$	4,976	$	4,976	$	14,926	$	14,926
	Income from discontinued operations, before tax	$	4,976	$	4,976	$	14,926	$	14,926
	Gain on sale of discontinued operations		250,000		250,000		250,000		250,000
	Income tax expense		-5,280		-		-5,280		-
	Net income from discontinued operations, net of tax	$	249,696	$	254,976	$	259,646	$	264,926

Income_Loss_Per_Share_of_Commo1

Income (Loss) Per Share of Common Stock (Tables)	9 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Schedule of Weighted Average Number of Shares [Table Text Block]	The number of weighted average common shares used in the calculation of basic EPS and diluted EPS were as follows:
		For the nine months ended				For the three months ended
		March 31,				March 31,
		2015		2014		2015		2014
	Basic shares		7,533,608		7,209,037		7,675,520		7,249,725
	Dilutive effect of stock options		509,368		-		638,154		681,077
	Diluted shares		8,042,976		7,209,037		8,313,674		7,930,802

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	9 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The fair values of the options granted during the nine months ended March 31, 2015 and 2014 were primarily estimated on the date of the grant using the Black-Scholes option-pricing model on the basis of the following weighted average assumptions during the respective periods:
			For the nine months ended
			March 31,
			2015			2014
	Risk-free interest rate			0.97	%		3	%
	Expected option life in years			6.5			6.5
	Expected stock price volatility			73.46	%		76.1	%
	Expected dividend yield			0	%		0	%
	Weighted-average fair value of options granted		$	5.46		$	3.95
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Changes in outstanding stock options during the nine months ended March 31, 2015 were as follows:
			Options
									Weighted
									Average
						Weighted			Remaining
						Average			Contractual		Aggregate
			Number of			Exercise			Life		Intrinsic
			Shares			Price ($)			(years)		Value (a)
	Outstanding as of June 30, 2014			1,663,329			3.88
	Granted			369,000			9.05
	Exercised			-545,713			4.06				$	1,478,776
	Forfeited			-13,500			4.01
	Expired			-28,000			8
	Outstanding as of March 31, 2015			1,445,116			5.05			6.6	$	11,576,608
	Exercisable and vested at March 31, 2015			650,256			3.27			5.3	$	6,362,511
	Available for grant as of March 31, 2015			958,975	*
	(a)	Intrinsic value for purposes of this table represents the amount by which the fair value of the underlying stock, based on the respective market prices at March 31, 2015 or if exercised, the exercise dates, exceeds the exercise prices of the respective options.
	*	Includes the recent 750,000 share 2014 Employee Equity Incentive Plan approved by shareholders at the annual meeting held on February 3, 2015.

Inventories_Tables

Inventories (Tables)	9 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	Inventories are summarized as follows:
		March 31,		June 30,
		2015		2014
	Raw material	$	2,056,238	$	1,820,046
	Work-in-process		521,669		410,827
	Finished goods		2,602,328		3,337,568
			5,180,235		5,568,441
	Less valuation reserve		1,015,894		1,351,091
		$	4,164,341	$	4,217,350

Accrued_Expenses_and_Other_Cur1

Accrued Expenses and Other Current Liabilities (Tables)	9 Months Ended
	Mar. 31, 2015
Payables and Accruals [Abstract]
Schedule of Accrued Expenses and Other Current Liabilities [Table Text Block]	The following summarizes accrued expenses and other current liabilities:
		March 31,		June 30,
		2015		2014
	Accrued payroll and vacation	$	463,188	$	460,341
	Accrued bonuses		225,000		250,000
	Accrued commissions		331,000		340,462
	Accrued professional and legal fees		86,378		85,832
	Deferred income		46,403		102,453
	Other		205,254		218,162
		$	1,357,223	$	1,457,250

Fair_Value_of_Financial_Instru1

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value, by Balance Sheet Grouping [Table Text Block]	The following is a summary of the carrying amounts and estimated fair values of our financial instruments at March 31, 2015 and June 30, 2014:
	March 31, 2015	Carrying Amount		Fair Value
	Cash and cash equivalents	$	8,909,275	$	8,909,275
	Trade accounts receivable		3,517,863		3,517,863
	Trade accounts payable		1,023,492		1,023,492
	June 30, 2014	Carrying Amount		Fair Value
	Cash and cash equivalents	$	7,039,938	$	7,039,938
	Trade accounts receivable		3,759,152		3,759,152
	Trade accounts payable		1,650,323		1,650,323

Goodwill_and_Intangible_Assets1

Goodwill and Intangible Assets (Tables)	9 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	The following is a schedule of estimated future amortization expense as of March 31, 2015:
				Customer		Reacquired
		Patents		Relationships		Contractual Rights
	2015	$	22,446	$	40,000	$	89,492
	2016		83,519		40,000		178,983
	2017		78,424		-		-
	2018		75,843		-		-
	2019		68,314		-		-
	Thereafter		245,421		-		-
		$	573,967	$	80,000	$	268,475

Related_Party_Transactions_Tab

Related Party Transactions (Tables)	9 Months Ended
	Mar. 31, 2015
Related Party Transactions [Abstract]
Schedule of Related Party Transactions [Table Text Block]	Set forth below is a table showing the Company’s net sales and accounts receivable for the indicated time periods below with Applied BioSurgical and MD Solutions:
	For the nine months ended March 31,
	Applied BioSurgical	2015		2014
	Sales	$	245,151	$	322,097
	Accounts receivable		64,534		130,354
	MD Solutions	2014
	Australasia PTY Ltd.
	Sales	$	116,158
	Accounts receivable		13,713
	For the three months ended March 31,
	Applied BioSurgical	2015		2014
	Sales	$	64,534	$	156,403
	Accounts receivable		64,534		130,354
	MD Solutions	2014
	Australasia PTY Ltd.
	Sales	$	40,805
	Accounts receivable		13,713

Basis_of_Presentation_Details

Basis of Presentation (Details) (USD $)	3 Months Ended		9 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Revenue from External Customer [Line Items]
Net sales	$5,314,797	$4,284,645	$15,455,142	$11,482,288
UNITED STATES
Revenue from External Customer [Line Items]
Net sales	2,607,023	2,258,370	7,709,102	5,667,183
AUSTRALIA
Revenue from External Customer [Line Items]
Net sales	161,858	40,805	313,221	116,158
SOUTH AFRICA
Revenue from External Customer [Line Items]
Net sales	64,535	156,403	245,151	322,097
EUROPE
Revenue from External Customer [Line Items]
Net sales	866,726	834,195	2,590,616	1,587,486
ASIA
Revenue from External Customer [Line Items]
Net sales	1,016,518	688,432	2,759,121	2,025,492
CANADA AND MEXICO
Revenue from External Customer [Line Items]
Net sales	272,700	183,827	513,916	616,172
SOUTH AMERICA
Revenue from External Customer [Line Items]
Net sales	96,087	100,373	615,295	810,977
MIDDLE EAST
Revenue from External Customer [Line Items]
Net sales	$229,350	$22,240	$708,720	$336,723

Basis_of_Presentation_Details_

Basis of Presentation (Details 1) (USD $)	3 Months Ended		9 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenues	$4,976	$4,976	$14,926	$14,926
Income from discontinued operations, before tax	4,976	4,976	14,926	14,926
Gain on sale of discontinued operations	250,000	250,000	250,000	250,000
Income tax expense	-5,280	0	-5,280	0
Net income from discontinued operations, net of tax	$249,696	$254,976	$259,646	$264,926

Basis_of_Presentation_Details_1

Basis of Presentation (Details Textual) (USD $)	3 Months Ended	1 Months Ended		9 Months Ended
	Mar. 31, 2015	Oct. 19, 2011	31-May-10	Mar. 31, 2015
Termination Agreement [Member]
Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies [Line Items]
Buy Back Amount Used For Customer Use	$28,867
Stock Repurchased During Period, Value	328,136
Laboratory and Forensic Safety Products Business [Member]
Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies [Line Items]
Proceeds from Sales of Business, Affiliate and Productive Assets		1,500,000
Sale of Business Potential Additional Payment		500,000
Sale of Business Potential Additional Payment Determination Basis		based upon 30% of net sales in excess of $2.0 million for each of the three years following the closing (the earn-out).
High Intensity Focused Ultrasound Technology [Member]
Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies [Line Items]
Proceeds from Sales of Intangible Assets			5,800,000
Sale of Intangible Assets Percentage of Gross Revenue Received as Earn Out Up to First Benchmark			7.00%
Proceeds from Sale of Intangible Assets First Benchmark			3,000,000
Sale of Intangible Assets Percentage of Gross Revenue Received as Earn Out Up to Second Benchmark			5.00%
Proceeds from Sale of Intangible Assets Second Benchmark			5,800,000
Payment Sale Of Intangible Assets Description			Commencing 90 days after each December 31st and beginning December 31, 2011 the payments will be the greater of (a) $250,000 or (b) 7% of gross revenues received up to the time the Company has received the first $3 million and thereafter 5% of gross revenues up to the $5.8 million.
Payment Sale Of Intangible Assets				$1,004,788
Fibra Sonics Ny Inc [Member]
Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies [Line Items]
Noncontrolling Interest, Ownership Percentage by Parent	100.00%			100.00%

Income_Loss_Per_Share_of_Commo2

Income (Loss) Per Share of Common Stock (Details)	3 Months Ended		9 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Basic shares	7,675,520	7,249,725	7,533,608	7,209,037
Dilutive effect of stock options	638,154	681,077	509,368	0
Diluted shares	8,313,674	7,930,802	8,042,976	7,209,037

Income_Loss_Per_Share_of_Commo3

Income (Loss) Per Share of Common Stock (Details Textual)	3 Months Ended		9 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	92,000	166,800	92,000	1,732,829

Comprehensive_IncomeLoss_Detai

Comprehensive Income/(Loss) (Details Textual) (USD $)	3 Months Ended		9 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	$454,340	$428,770	$1,738,734	$4,106

StockBased_Compensation_Detail

Stock-Based Compensation (Details) (USD $)	9 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	0.97%	3.00%
Expected option life in years	6 years 6 months	6 years 6 months
Expected stock price volatility	73.46%	76.10%
Expected dividend yield	0.00%	0.00%
Weighted-average fair value of options granted	$5.46	$3.95

StockBased_Compensation_Detail1

Stock-Based Compensation (Details 1) (Employee Stock Option [Member], USD $)	9 Months Ended
	Mar. 31, 2015
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding at beginning of period	1,663,329
Number of Shares, Granted	369,000
Number of Shares, Exercised	-545,713
Number of Shares, Forfeited	-13,500
Number of Shares, Expired	-28,000
Number of Shares, Outstanding at end of period	1,445,116
Number of Shares, Exercisable and vested	650,256
Number of shares, Available for grant	958,975	[1]
Weighted Average Exercise Price, Outstanding at beginning of period	$3.88
Weighted Average Exercise Price, Granted	$9.05
Weighted Average Exercise Price, Exercised	$4.06
Weighted Average Exercise Price, Forfeited	$4.01
Weighted Average Exercise Price, Expired	$8
Weighted Average Exercise Price, Outstanding at end of period	$5.05
Weighted Average Exercise Price, Exercisable and vested	$3.27
Weighte Average Remaining Contractual Life, Outstanding (in years)	6 years 7 months 6 days
Weighte Average Remaining Contractual Life, Exercisable and vested (in years)	5 years 3 months 18 days
Aggregate Intrinsic Value, Exercised (in dollars)	$1,478,776	[2]
Aggregate Intrinsic Value, Outstanding (in dollars)	11,576,608	[2]
Aggregate Intrinsic Value, Exercisable and vested (in dollars)	$6,362,511	[2]
[1]	Includes the recent 750,000 share 2014 Employee Equity Incentive Plan approved by shareholders at the annual meeting held on February 3, 2015.
[2]	Intrinsic value for purposes of this table represents the amount by which the fair value of the underlying stock, based on the respective market prices at March 31, 2015 or if exercised, the exercise dates, exceeds the exercise prices of the respective options.

StockBased_Compensation_Detail2

Stock-Based Compensation (Details Textual) (USD $)	9 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Feb. 03, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award	not to exceed 10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period	369,000	324,000
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options	$2,920,000
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition 1	3 years
Allocated Share-based Compensation Expense	763,000	509,000
Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%
Employee Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized			750,000
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Cash Received from Exercise of Stock Options	$555,897
Treasury Stock, Shares, Acquired	47,422
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period	545,713
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares	13,500
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Expirations In Period	28,000

Income_Taxes_Details_Textual

Income Taxes (Details Textual) (USD $)	3 Months Ended		9 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Income Taxes [Line Items]
Income Tax Expense (Benefit)	$8,406	$8,376	$56,223	$13,876
Effective Income Tax Rate Reconciliation, Percent			4.00%	-6.00%

Inventories_Details

Inventories (Details) (USD $)	Mar. 31, 2015	Jun. 30, 2014
Inventory [Line Items]
Raw material	$2,056,238	$1,820,046
Work-in-process	521,669	410,827
Finished goods	2,602,328	3,337,568
Inventory, Gross	5,180,235	5,568,441
Less valuation reserve	1,015,894	1,351,091
Inventory, Net, Total	$4,164,341	$4,217,350

Accrued_Expenses_and_Other_Cur2

Accrued Expenses and Other Current Liabilities (Details) (USD $)	Mar. 31, 2015	Jun. 30, 2014
Accrued Liabilities, Current [Abstract]
Accrued payroll and vacation	$463,188	$460,341
Accrued bonuses	225,000	250,000
Accrued commissions	331,000	340,462
Accrued professional and legal fees	86,378	85,832
Deferred income	46,403	102,453
Other	205,254	218,162
Accrued Expenses and Other Current Liabilities	$1,357,223	$1,457,250

Commitment_and_Contingencies_D

Commitment and Contingencies (Details Textual) (USD $)	3 Months Ended	9 Months Ended
	Dec. 31, 2013	Mar. 31, 2015
Commitments and Contingencies [Line Items]
Cost Of Goods Sold Reversal Adjustment	$439,508
Employment Contracts [Member]
Commitments and Contingencies [Line Items]
Employment Expiration Date		30-Jun-15
Michael A McManus [Member]
Commitments and Contingencies [Line Items]
Salaries, Wages and Officers' Compensation		299,000

Fair_Value_of_Financial_Instru2

Fair Value of Financial Instruments (Details) (USD $)	Mar. 31, 2015	Jun. 30, 2014	Mar. 31, 2014	Jun. 30, 2013
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and cash equivalents, Carrying Amount	$8,909,275	$7,039,938	$5,648,200	$5,806,437
Trade accounts receivable, Carrying Amount	3,517,863	3,759,152
Trade accounts payable, Carrying Amount	1,023,492	1,650,323
Cash and cash equivalents, Fair Value	8,909,275	7,039,938
Trade accounts receivable, Fair Value	3,517,863	3,759,152
Trade accounts payable, Fair Value	$1,023,492	$1,650,323

Goodwill_and_Intangible_Assets2

Goodwill and Intangible Assets (Details) (USD $)	Mar. 31, 2015	Jun. 30, 2014
Patents [Member]
2015	$22,446
2016	83,519
2017	78,424
2018	75,843
2019	68,314
Thereafter	245,421
Finite-Lived Intangible Assets, Future Amortization Expense	573,967	611,355
Customer Relationships [Member]
2015	40,000
2016	40,000
2017	0
2018	0
2019	0
Thereafter	0
Finite-Lived Intangible Assets, Future Amortization Expense	80,000	200,000
Contractual Rights [Member]
2015	89,492
2016	178,983
2017	0
2018	0
2019	0
Thereafter	0
Finite-Lived Intangible Assets, Future Amortization Expense	$268,475	$0

Goodwill_and_Intangible_Assets3

Goodwill and Intangible Assets (Details Textual) (USD $)	3 Months Ended		9 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014	Jun. 30, 2014
Patents [Member]
Finite-Lived Intangible Asset, Useful Life			17 years
Finite-Lived Intangible Assets, Net	$573,967		$573,967		$611,355
Finite-Lived Intangible Assets, Accumulated Amortization	768,817		768,817		641,469
Amortization of Intangible Assets	22,000	22,000	127,000	63,000
Customer Relationships [Member]
Finite-Lived Intangible Assets, Net	80,000		80,000		200,000
Finite-Lived Intangible Assets, Accumulated Amortization	720,000		720,000		600,000
Amortization of Intangible Assets	40,000	40,000	120,000	120,000
Contractual Rights [Member]
Finite-Lived Intangible Assets, Net	268,475		268,475		0
Finite-Lived Intangible Assets, Accumulated Amortization	59,661		59,661		0
Amortization of Intangible Assets			$59,661	$0

Related_Party_Transactions_Det

Related Party Transactions (Details) (USD $)	3 Months Ended		9 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Applied BioSurgical [Member]
Related Party Transaction [Line Items]
Sales	$64,534	$156,403	$245,151	$322,097
Accounts receivable	64,534	130,354	64,534	130,354
MD Solutions Australasia PTY Ltd [Member]
Related Party Transaction [Line Items]
Sales		40,805		116,158
Accounts receivable		$13,713		$13,713

Licensing_Agreements_for_Medic1

Licensing Agreements for Medical Technology (Details Textual) (USD $)	9 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Proceeds from License Fees Received	$475,000
Proceeds from Royalties Received	$3,140,000	$2,463,000
License Agreement Expiration Period	2016-10